PatientsLikeMe Names Greg Ploussios Senior Vice President and General Counsel

09:00 EDT 2 Aug 2017 | Businesswire

PatientsLikeMe announced today that it has named Greg Ploussios to the newly-created role of Senior Vice President and General Counsel. Prior to joining PatientsLikeMe, Ploussios served as the company’s outside counsel for over a decade, advising and negotiating PatientsLikeMe’s licensing, collaboration and commercial agreements and representing the company in equity financing, mergers and acquisitions, and other corporate matters, including its recent financing and partnership with iCarbonX. As Senior Vice President and General Counsel, Ploussios will take a more active role in overseeing PatientsLikeMe’s legal needs, including licensing, collaboration and commercial agreements, equity financing, privacy, and regulatory compliance.

This Smart News Release features multimedia. View the full release here:

Greg Ploussios is PatientsLikeMe's new Senior Vice President and General Counsel (Photo: Business Wi ...

Greg Ploussios is PatientsLikeMe's new Senior Vice President and General Counsel (Photo: Business Wire)

Before joining PatientsLikeMe, Ploussios was a partner at Foley Hoag LLP in the business department, where he co-chaired the firm’s Licensing & Strategic Alliance Practice. Prior to that he was a partner at Edwards Angell Palmer & Dodge LLP. Ploussios’s practice has focused on representing information technology, software, Internet, bioinformatics, and medical device clients with an emphasis on licensing and commercial transactions, as well as venture capital and private equity investments and general corporate representation. Ploussios has advised numerous technology startups as well as more mature companies, including PTC, Delphi Technology, Nlyte Software, Karen Clark & Company, and Houghton Mifflin Harcourt Publishing. Ploussios started his legal career in 1996 as a summer associate at Palmer & Dodge LLP.

“What I love about Greg is he's a lawyer who codes for fun. His unique mix of technical knowledge and legal acumen has made him an invaluable advisor over the years," said Co-Founder and President Ben Heywood. “He’ll be an even greater asset as a partner in the business as we explore new frontiers where ethical, legal and regulatory questions converge.”

Ploussios holds a Juris Doctor from Boston University School of Law and a Bachelor of Arts degree from the University of Michigan, with a double major in English and Political Science. He resides in Newton, Massachusetts.

About PatientsLikeMe
PatientsLikeMe, the world’s largest personalized health network, helps people find new options for treatments, connect with others, and take action to improve their outcomes. The company has worked with every major pharmaceutical company and a range of government organizations to bring the patient voice to research, development and public policy. With more than 500,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 100 research studies. Visit us at or follow us via our blog, Twitter or Facebook.

Margot Carlson Delogne, +1-781-492-1039


More From BioPortfolio on "PatientsLikeMe Names Greg Ploussios Senior Vice President and General Counsel"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.